Fresenius Medical Care AG & Co. KGaA

TickerFME.XETRA
Current Price –
Fresenius Medical Care AG & Co. KGaA – stock chart

5-year stock timeline

2026 October — CEO appointment signals fresh leadership phase

Shervin J. Korangy was appointed CEO and Chairman of the Management Board effective October 12, 2026, replacing Helen Giza. The market interpreted the change as continuity of strategic execution rather than a pivot, with investor sentiment tilting toward expectations of further operational delivery and shareholder returns under renewed leadership. The appointment arrived amid demonstrated progress: Q2 2026 revenue reached EUR 4,861m with organic growth of 5% year-over-year, framing the leadership transition within an improved operating performance context.[1][15][2]

2026 mid-year — Accelerated capital returns and buyback completion

The company completed its announced €1.0bn share buyback program (24,848,819 shares repurchased between August 11, 2025 and April 30, 2026) and secured AGM approval of a €1.49 dividend for FY2025, paid May 27, 2026. Investors read the accelerated buyback and rising dividend as management confidence in cash generation and a deliberate shift toward shareholder-friendly capital allocation following the FME25 turnaround. The reduced free float and accretive EPS effects were expected to support valuation multiples.[5][8][3]

2026 February — FY2025 results confirm margin step-up and earnings acceleration

Fresenius Medical Care reported FY2025 operating income growth of 27% and EPS growth of 44%, reaching the upper end of guidance with group operating margin stepping to approximately 11.3%. The results reinforced a narrative shift from turnaround to growth and margin expansion, prompting upward revisions in investor expectations for sustained operating leverage and free cash flow. Company messaging emphasized FME25 execution and product commercialization, particularly the 5008X CAREsystem U.S. launch.[12][10]

2025 August through April 2026 — Share buyback program executed in two tranches

The company launched a €1.0bn share repurchase program in June 2025 and completed execution across two tranches: first tranche of 14,124,564 shares for approximately €586m (completed December 29, 2025); second tranche of 10,724,255 shares for approximately €414m (completed April 30, 2026). Active capital return signaled a pivot from restructuring to shareholder value delivery, with buybacks viewed as management confidence in sustainable cash flow and a mechanism to lift EPS while reducing leverage.[4][5][9]

2025 May — FDA clearance of 5008X CAREsystem and commercialization launch

The U.S. Food and Drug Administration cleared the hemodiafiltration-capable 5008X CAREsystem in May 2025, with commercial launch beginning in 2026. The milestone reinforced the growth narrative around product innovation and clinical differentiation in core dialysis equipment. Investors identified potential for modest revenue mix benefits and long-term equipment upgrade cycles supporting recurring revenue growth in U.S. clinics.[10][13]

2025 year-end — FME25 turnaround objectives effectively achieved

The company reported that FME25 turnaround objectives were met by end of 2025, including operating margin improvement, deleveraging, and portfolio optimization through divestments and restructuring. The market narrative shifted from turnaround to execution and acceleration, with management credibility strengthened. Expectation of consistent dividend policy and continued capital returns replaced prior uncertainty around sustainability.[10][9]

2024 December and 2025 March — DAX 40 inclusion and Fresenius SE stake reduction

Fresenius Medical Care was included in the DAX 40 in December 2024. In March 2025, Fresenius SE announced reduction of its stake from approximately 32.2% to 25% plus one share. Listing status and ownership changes increased free-float liquidity and governance independence. Investors viewed deconsolidation from Fresenius SE and the reduced anchor stake as enabling more direct public market valuation and autonomous capital allocation decisions.[14][4]

2023 July through November — Legal form conversion and governance simplification

Shareholders approved conversion from a KGaA to an AG at an extraordinary general meeting on July 14, 2023, with conversion becoming effective upon registration on November 30, 2023. Fresenius SE ceased to control the company under IFRS 10 upon registration. The market perceived the conversion as a decisive governance and strategic inflection that simplified corporate structure and increased autonomy. Investors saw it as removing structural constraints that had complicated minority shareholder influence, helping reset expectations for transparency and capital allocation.[4][6]

2023 — Portfolio optimization and operational restructuring

The company divested several non-core assets including National Cardiovascular Partners in the U.S., Argentina operations, and Cura Day Hospitals Group in Australia, generating approximately €0.5bn in total proceeds (€135m received in 2023). These moves reinforced the turnaround narrative by reducing complexity and focusing on core dialysis businesses. Investor confidence in management's ability to simplify and refocus toward higher-margin operations strengthened materially.[6]

2022–2023 — Post-pandemic recovery and margin program implementation

The company navigated post-COVID headwinds including evolving U.S. federal relief funding effects while implementing FME25 cost and margin initiatives. Operating income and margins were in the earlier recovery phase. Investors viewed Fresenius Medical Care as in a multi-year operational recovery, with debates centered on whether the company could sustainably improve margins and deleverage. 2022–2023 were viewed as execution years where management credibility was being rebuilt. The company cited prior leverage of approximately 3.4x in 2022 and targeted margin bands of 10–14% as part of FME25 medium-term objectives, later achieved by 2025.[9][10]

2021–2022 — Dividend continuity and baseline capital structure

The company maintained regular dividend policy (dividend per share of €1.35 for 2021, paid May 17, 2022) and secured shareholder authorizations for buybacks, with AGM authorization extending buyback capacity through May 19, 2026. The company was viewed as a stable European healthcare dividend compounder despite operational challenges, with investor focus on balancing cash returns against necessary reinvestment and restructuring spending.[4][8]

Key risks and downside factors

Fresenius Medical Care operates as the largest vertically integrated player in dialysis, combining manufacturing with clinic operations. The competitive landscape fragments across clinic operators like DaVita, Diaverum, and Satellite Healthcare on one side, and device and consumables suppliers like Baxter, B. Braun, Nipro, Nikkiso, and Outset on the other. The company faces material headwinds from reimbursement and regulatory tightening across its major markets, execution challenges as it scales global service offerings, intensifying competition from specialized device makers and home-dialysis providers, and structural vulnerabilities in its consumables and equipment supply chains where manufacturing concentration creates dependency risks.

  • Reimbursement and regulatory risk: shifts in Medicare or insurer reimbursement policies, pricing caps, or tightened clinical and regulatory requirements across the US, Germany, and other key markets can materially compress clinic margins and constrain device pricing [major revenue exposure].
  • Specialist device makers and new entrants focused on home dialysis and digital care platforms pose a competitive threat. They could capture share in machines, home therapies, or value-based kidney-care contracts, which would likely pressure both pricing and utilization rates [8], [3].
  • A large clinic footprint introduces operational and integration challenges that compound with scale. Staffing shortages and labor cost inflation create margin pressure, while the difficulty of integrating acquisitions and standardizing clinical quality across thousands of facilities can drive costs higher and increase regulatory exposure.
  • Fresenius depends on internally produced consumables and operates from concentrated production sites. Disruptions at these facilities—whether from component shortages, manufacturing problems, or quality issues—could interrupt clinic operations and revenue.

Competitive landscape

Fresenius Medical Care (FMS / FME.XETRA) holds the largest global dialysis footprint and manufactures dialysis equipment and consumables at scale. Its competitive position faces pressure from two directions: vertically integrated U.S. dialysis operators that control their own supply chains, and diversified medical-device conglomerates with meaningful renal product portfolios. The market itself fragments across clinic operators competing on scale and contract terms, specialized renal-device makers focused on machines and dialyzers, and regional or private clinic networks. The business carries material risks around reimbursement and regulatory tightening, the labor and capital intensity of running clinic networks, the possibility of technological displacement in treatment modalities, and the concentration of revenue within renal care markets specifically.

Private competitors

  • Satellite Healthcare
  • U.S. Renal Care
  • Vantive (private renal specialist / regional player)
  • Dialyze Direct

Get More Stock Analyses Like This

Receive hand-picked stock recommendations with detailed analyses every week

Start Free Trial

Performance Figures of Fresenius Medical Care AG & Co. KGaA

in EUR

1M High / Low
42.60 / 37.79
52W High / Low
45.90 / 34.57
5Y High / Low
63.66 / 25.95
1M
-2.28%
3M
-3.94%
6M
+3.49%
1Y
+1.47%
3Y
+19.09%
5Y
-20.02%

Relative Performance vs Benchmarks

PeriodFresenius Medical Care AG & Co. KGaA vs DAX vs S&P 500 (SPY)
1M -2.28% -3.99% +2.77%
3M -3.94% -2.41% +0.46%
6M +3.49% +0.08% +5.06%
1Y +1.47% -9.64% -9.92%
3Y +19.09% -42.76% -47.59%
5Y -20.02% -79.28% -86.53%

Get More Stock Analyses Like This

Receive hand-picked stock recommendations with detailed analyses every week

Start Free Trial

Historical valuation trends

How the company’s key valuation ratios (P/E, P/S, P/B and P/CF) have evolved over time compared to today.

PeriodP/E RatioP/S RatioP/B RatioP/CF Ratio
Current12.30.50.83.5
1Y ago16.10.60.94.6
3Y ago19.00.50.84.2
5Y ago18.01.01.46.9

Frequently Asked Questions

Where is the Fresenius Medical Care AG & Co. KGaA stock traded?

The Fresenius Medical Care AG & Co. KGaA stock trades under the ticker FME.XETRA on the XETRA exchange. ISIN: DE0005785802.

What does Fresenius Medical Care AG & Co. KGaA do?

Fresenius Medical Care AG & Co. KGaA is a company characterized by the following investment thesis:

What are the key metrics for FME.XETRA?

Key metrics for FME.XETRA include valuation (P/E 13.3, P/S 0.5, P/B 0.8), profitability (profit margin 4.22%, ROE 6.39%), and growth (revenue –, earnings –). Market capitalization is 10.31B EUR. These metrics give an overview of the company's financial performance and valuation.

How has Fresenius Medical Care AG & Co. KGaA's stock price performed?

Fresenius Medical Care AG & Co. KGaA's stock has returned – over 1 year, – over 3 years, and – over 5 years. Performance can vary depending on market conditions and company developments.

How is FME.XETRA valued?

FME.XETRA has the following valuation metrics: P/E Ratio: 13.3, P/S Ratio: 0.5, P/B Ratio: 0.8. These metrics help assess whether the stock is fairly valued compared to its fundamentals.

Does FME.XETRA pay dividends?

Yes, FME.XETRA pays dividends with a dividend yield of 3.7%. Dividends can be an important component of the total return on an investment.

What are the key risks when investing in FME.XETRA?

Key risks for FME.XETRA include: Fresenius Medical Care operates as the largest vertically integrated player in dialysis, combining manufacturing with clinic operations. The competitive landscape fragments across clinic operators like DaVita, Diaverum, and Satellite Healthcare on one side, and device and consumables suppliers like Baxter, B. Braun, Nipro, Nikkiso, and Outset on the other. The company faces material headwinds from reimbursement and regulatory tightening across its major markets, execution challenges as it scales global service offerings, intensifying competition from specialized device makers and home-dialysis providers, and structural vulnerabilities in its consumables and equipment supply chains where manufacturing concentration creates dependency risks.
  • Reimbursement and regulatory risk: shifts in Medicare or insurer reimbursement policies, pricing caps, or tightened clinical and regulatory requirements across the US, Germany, and other key markets can materially compress clinic margins and constrain device pricing [major revenue exposure].
  • Specialist device makers and new entrants focused on home dialysis and digital care platforms pose a competitive threat. They could capture share in machines, home therapies, or value-based kidney-care contracts, which would likely pressure both pricing and utilization rates [8, 3, 21].
  • A large clinic footprint introduces operational and integration challenges that compound with scale. Staffing shortages and labor cost inflation create margin pressure, while the difficulty of integrating acquisitions and standardizing clinical quality across thousands of facilities can drive costs higher and increase regulatory exposure.
  • Fresenius depends on internally produced consumables and operates from concentrated production sites. Disruptions at these facilities—whether from component shortages, manufacturing problems, or quality issues—could interrupt clinic operations and revenue.
Investors should consider these risk factors carefully before making an investment decision.

Who are the main competitors of Fresenius Medical Care AG & Co. KGaA?

Fresenius Medical Care AG & Co. KGaA competes with several listed peers in its sector. Fresenius Medical Care (FMS / FME.XETRA) holds the largest global dialysis footprint and manufactures dialysis equipment and consumables at scale. Its competitive position faces pressure from two directions: vertically integrated U.S. dialysis operators that control their own supply chains, and diversified medical-device conglomerates with meaningful renal product portfolios. The market itself fragments across clinic operators competing on scale and contract terms, specialized renal-device makers focused on machines and dialyzers, and regional or private clinic networks. The business carries material risks around reimbursement and regulatory tightening, the labor and capital intensity of running clinic networks, the possibility of technological displacement in treatment modalities, and the concentration of revenue within renal care markets specifically.
  • DaVita Inc. (DVA.NYSE)
  • Baxter International Inc. (BAX.NYSE)
  • Koninklijke Philips N.V. (PHIA.AMS)
These competitors influence pricing power, growth opportunities and relative valuation.

When does Fresenius Medical Care AG & Co. KGaA report earnings?

Fresenius Medical Care AG & Co. KGaA's next earnings report date is February 23, 2027.

Key Metrics

Market Capitalization
10.31B EUR
P/E Ratio
13.33
Analyst Target Price
–

Valuation Metrics

P/S Ratio
0.53
P/B Ratio
0.81

Profitability Metrics

Profit Margin
4.22%
Operating Margin
10.30%
Return on Equity
6.39%
Return on Assets
2.64%

Growth Metrics

Revenue Growth
–
Earnings Growth
–

Dividend history

Long-term record of paid dividends (amount per share and dividend yield at the time of payment).

YearDividendYield at paymentAvg. yield
20261.49 EUR3.84%1.91%
20251.44 EUR2.74%
20241.19 EUR2.85%
20231.12 EUR2.54%
20221.35 EUR2.39%
20211.34 EUR1.98%
20201.20 EUR1.65%
20201.20 EUR1.64%
20191.17 EUR1.65%
20181.06 EUR1.20%
20170.96 EUR1.12%
20160.80 EUR1.08%
20150.78 EUR0.98%
20140.77 EUR1.60%
20130.75 EUR1.42%

Earnings history & estimates

Historical earnings performance shows how consistently the company meets or exceeds analyst expectations. Forward estimates provide insight into expected profitability and growth trajectory.

Historical earnings performance

43.8%
Beat estimate
51.6%
Miss estimate
+9.73%
Avg surprise when beat
-14.97%
Avg surprise when miss

Reports analyzed: 64

Upcoming earnings report

February 23, 2027
Next earnings date

Analyst estimates for upcoming periods

Next year
December 31, 2027
Consensus3.83
Range3.34 – 4.56
15 analysts
Est. growth vs prior: -5.3%
Revisions: 7d ↑0 ↓0 · 30d ↑2 ↓8
Next quarter
March 31, 2027
Consensus0.77
Range0.77 – 0.77
1 analysts
Est. growth vs prior: -14.95%

Key financial figures

All figures in EUR

Selected income statement, balance sheet and cash flow figures. Annual and quarterly, based on reported IFRS/GAAP financials.

20252024202320222021
Revenue19.63B19.34B19.45B19.40B17.62B
Operating income (EBIT)1.83B1.39B1.37B1.54B301.32M
Net income978.00M537.91M499.00M673.40M969.31M
Free cash flow1.77B1.69B1.94B756.00M806.00M
Total assets31.00B33.57B33.93B35.75B34.37B
Equity13.31B14.58B13.62B15.45B13.98B
Net debt9.20B9.83B10.65B11.94B11.84B
© Leeway
PWP Leeway UG (haftungsbeschränkt)
Leeway Icon